Gail Boxer Marcus Sells 9,682 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 9,682 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $159.98, for a total transaction of $1,548,926.36. Following the completion of the sale, the director now owns 9,704 shares of the company’s stock, valued at $1,552,445.92. The trade was a 49.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Gail Boxer Marcus also recently made the following trade(s):

• On Thursday, November 14th, Gail Boxer Marcus sold 2,212 shares of Natera stock. The stock was sold at an average price of $158.53, for a total transaction of $350,668.36.

Natera Stock Down 1.2 %

NTRA stock opened at $167.26 on Friday. The stock has a market cap of $22.08 billion, a P/E ratio of -95.03 and a beta of 1.53. Natera, Inc. has a 1-year low of $53.62 and a 1-year high of $171.95. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock’s fifty day simple moving average is $130.72 and its two-hundred day simple moving average is $117.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera’s revenue for the quarter was up 63.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.95) earnings per share. Analysts expect that Natera, Inc. will post -1.66 EPS for the current year.

Institutional Trading of Natera

Several hedge funds and other institutional investors have recently modified their holdings of NTRA. Coldstream Capital Management Inc. purchased a new position in shares of Natera in the third quarter valued at $305,000. Geode Capital Management LLC raised its stake in Natera by 7.4% in the third quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock valued at $265,747,000 after purchasing an additional 143,825 shares in the last quarter. M&T Bank Corp lifted its holdings in shares of Natera by 7.9% during the 3rd quarter. M&T Bank Corp now owns 5,513 shares of the medical research company’s stock worth $699,000 after acquiring an additional 405 shares during the last quarter. Gordian Capital Singapore Pte Ltd grew its position in Natera by 211.5% in the third quarter. Gordian Capital Singapore Pte Ltd now owns 8,193 shares of the medical research company’s stock worth $1,040,000 after acquiring an additional 5,563 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in Natera in the third quarter valued at $1,267,000. Institutional investors own 99.90% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. UBS Group cut their price target on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Leerink Partners upped their price objective on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Stephens reiterated an “overweight” rating and set a $125.00 price objective on shares of Natera in a report on Friday, August 9th. TD Cowen upped their target price on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, Morgan Stanley lifted their price target on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $140.59.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.